Boston Scientific beats by $0.01, beats on revs; guides Q1 EPS in-line, revs in-line; guides FY17 EPS in-line, revs in-line
- Reports Q4 (Dec) earnings of $0.30 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.29; revenues rose 10.8% year/year to $2.19 bln vs the $2.16 bln Capital IQ Consensus. Grew organic revenue 10 percent in the fourth quarter over the prior year period. Organic revenue growth excludes the impact of changes in foreign currency exchange rates and sales from the acquisition of EndoChoice Holdings, Inc. (EndoChoice).
- Achieved excellent fourth quarter revenue growth in all segments, all compared to the prior year period: Medsurg: 13 percent (12 percent operational and 11 percent organic) Cardiovascular: 11 percent reported, operational and organic Rhythm Management: 7 percent reported, operational and organic
- Delivered revenue growth in all regions, all compared to the prior year period
- Co issues in-line guidance for Q1, sees EPS of $0.29-0.31, excluding non-recurring items, vs. $0.29 Capital IQ Consensus Estimate; sees Q1 revs of $2.05-2.10 bln vs. $2.08 bln Capital IQ Consensus Estimate.
- Co issues in-line guidance for FY17, sees EPS of $1.22-1.26, excluding non-recurring items, vs. $1.26 Capital IQ Consensus Estimate; sees FY17 revs of $8.675-8.875 bln vs. $8.8 bln Capital IQ Consensus Estimate.